. Author manuscript; available in PMC: 2010 Apr 1.

Published in final edited form as: Eur J Pharmacol. 2009 Apr 1;607(1-3):251–257. doi: 10.1016/j.ejphar.2009.01.042

Table 3.

Average hepatic arterial, portal, and total hepatic blood flow during the basal and experimental periods in conscious 42-h-fasted dogs given saline, or a low or high dose escitalopram infusion into the hepatic portal vein

		Experimental Period
Group	Basal Period	Period 1	Period 2
Average Hepatic Arterial Blood Flow (ml/kg/min)
SAL	5.1±0.4	5.9±0.5	6.8±0.9
L-ESC	5.2±0.4	5.9±0.8	6.9±1.1
H-ESC	5.0±0.2	5.5±0.3	6.0±0.6
Average Hepatic Portal Blood Flow (ml/kg/min)
SAL	22.6±1.4	17.9±1.2^a	17.9±1.2^a
L-ESC	25.6±0.7	18.3±0.8^a	17.3±0.6^a
H-ESC	21.4±1.7	16.3±1.2^a	17.4±1.1
Average Total Hepatic Blood Flow (ml/kg/min)
SAL	27.7±1.4	23.8±1.4	24.7±1.4
L-ESC	30.8±0.9	24.2±1.4^a	24.8±1.5
H-ESC	26.4±1.7	21.8±1.4	23.5±1.2

Data are mean ± S.E.M.. n=11 dogs in the saline group (SAL), n=6 in the group that received escitalopram at 2 μg/kg/min (L-ESC) and n=7 in the group that received escitalopram at 8 μg/kg/min (H-ESC)

Significant statistical difference (P<0.05) from basal period within the group